Shinobi Therapeutics, Inc.

Shinobi Therapeutics, Inc. is a US-based company focused on developing advanced immuno-oncology therapies utilizing induced pluripotent stem cells (iPSCs) to create immune-evasive cell treatments for various cancers and autoimmune diseases. Founded in 2022 and headquartered in South San Francisco, US, Shinobi Therapeutics, Inc. specializes in innovative immuno-oncology solutions.

The company is known for its unique approach to developing immune-evasive cell therapies, without any noted pivots or changes in its business strategy since inception. The firm has completed one deal as of August 7, 2024. Shinobi Therapeutics specializes in the development of innovative immuno-oncology therapies that leverage induced pluripotent stem cells (iPSCs) to create immune-evasive cell therapies. Their core offerings include engineered iPS-αβ T cells and iPS-NK cells designed to treat various cancers, including hepatocellular carcinoma (HCC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and glioblastoma, as well as autoimmune diseases.

The company's technology addresses the critical issue of immune rejection, enhancing the compatibility of therapies with the patient’s immune system. Shinobi's products are primarily targeted at healthcare providers, hospitals, and research institutions globally, particularly within markets such as North America, Europe, and Asia, where there is a significant demand for advanced cancer treatments and therapies for autoimmune disorders. Shinobi Therapeutics generates revenue through strategic partnerships and collaborations with leading institutions in the biopharmaceutical sector, alongside the development of proprietary cell therapies. The company engages in B2B transactions, primarily forming alliances with hospitals, research institutions, and pharmaceutical companies to facilitate the advancement and commercialization of its products.

Revenue streams may include licensing agreements for their immune-evasive technologies and potential sales of their therapeutic solutions, such as their flagship iPS-αβ T cell and iPS-NK cell therapies. The pricing structure for these services is determined through negotiated agreements, reflecting the specialized nature of their offerings and the value derived from their technology. In August 2024, Shinobi Therapeutics, Inc. raised an undisclosed amount of venture funding to support the advancement of its innovative cell therapies, specifically addressing challenges in the field with their low-immunogenicity iPS cell-derived T cell technology.

The company plans to enhance its product offerings and is exploring entry into new markets across North America, Europe, and Asia, aiming for expansion by 2025.